Depot injections and tardive dyskinesia.
A prospective study was undertaken on 374 out-patients receiving depot fluphenazine or depot flupenthixol to determine the incidence of tardive dyskinesia. In three years the percentage showing the bucco-linguo-masticatory syndrome rose from 8 per cent to 22 per cent, though patients had received various neuroleptics for a mean of 13 years previously. Fluphenazine and flupenthixol were equally involved though 75 per cent of affected patients had the condition in mild degree. Six additional cases of generalized chorea were all receiving flupenthixol. Reduction of dose or the substitution of pimozide produced marked improvement, but results suggest that it is unlikely that this will be permanent. Substitution of depot fluspirilene also produced favourable results. Careful monitoring, minimal neuroleptic dosage, and periods of neuroleptic abstinence are recommended.
D002819:Chorea / Q000139:chemically induced; D003692:Delayed-Action Preparations; D004409:Dyskinesia, Drug-Induced / Q000209:etiology*; D005260:Female; D005475:Flupenthixol / Q000008:administration & dosage / Q000009:adverse effects*; D005476:Fluphenazine / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D007267:Injections; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012559:Schizophrenia / Q000188:drug therapy; D013892:Thioxanthenes / Q000009:adverse effects*
D003692:Delayed-Action Preparations; D013892:Thioxanthenes; D005475:Flupenthixol; D005476:Fluphenazine